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revealed induction of class 11 mRNA), whereas this agent blocked the actions of TNF (16) ; cycloheximide appeared to have no effect on IFN--y actions on EC. These data raised the possibility that IFN-a or IFN-fl, induced by TNF or LT, could mediate the actions of TNF and LT on MHC antigen expression. Here we report that the actions of TNF and LT can be clearly distinguished from those of IFN-a/# by examining the effects of these cytokines in the presence of IFN-y. Specifically, LT and TNF act synergistically with IFN-y to enhance class I MHC expression and do not significantly affect IFN-y-mediated class 11 induction, whereas IFN-a and IFN-,B are, at most, additive with IFN-y for class I enhancement and strikingly inhibit the actions of IFN-y on class 11 expression . In addition, LT or TNF can further enhance the expression of MHC antigens induced by optimal levels of IFN-a or IFN-# . These new data make it seem highly unlikely that LT or TNF regulate MHC antigen expression in EC by inducing the synthesis of IFN-a or IFN-,# . Finally, experiments with rIL-6 (previously called 26-kD protein, IFN -R2 or B cell stimulating factor 2) do not support the alternative hypothesis (18, 19) that this cytokine mediates the actions of LT or TNF upon MHC expression in human EC since our IL-6 preparation has no detectable effect on the levels of MHC antigen expression . We conclude that there are at least three different classes of regulatory cytokines, LT/TNF, IFN-a/,0, and IFN-y, each of which has distinct effects upon EC expression of MHC antigens .
Materials and Methods
Human EC, isolated by collagenase treatment from umbilical vein segments, were pooled (two to six donors) and serially subcultured using conditions described elsewhere (20, 21) . Selected experiments, where indicated, were performed with EC cultured from a single umbilical vein segment (i.e., derived from one donor). All cultures in these experiments were used between passage level 3 and 8. Cytokines, expressed as products of recombinant cDNA clones or genes, were added to the cultures in complete standard medium (Medium 199 ; Biofluids, Rockville, MD) supplemented with 20% FCS, glutamine, antibiotics (all from Gibco Laboratories, Grand Island, NY), endothelial cell growth supplement (50 Ag/ml; Collaborative Research, Lexington, MA), and porcine intestinal heparin (100 Ag/ml, Sigma Chemical Co., St. Louis, MO) at the final concentrations indicated. The specific recombinant cytokine preparations used in these studies included TNF (expressed in Escherichia coli and purified to 2.5 X 10' U/mg in L929 cytotoxicity assays, reference 22), LT (cDNA cloned from RPMI 1788 cells and expressed in Chinese hamster ovary cells, partially purified to a concentration of 1 .5 X 105 U/ml in L929 cytotoxicity assays), IFN-1S (expressed in E. coli and purified to 108 U/mg, antiviral activity, reference 23), IFN-y (cDNA expressed in Chinese hamster ovary cells, partially purified to a concentration of 2 X 105 U/ml antiviral activity, reference 24), and IL-6 (cDNA expressed in yeast, partially purified to a concentration of 8 .7 X 105 U/ml in B cell stimulating factor 2 assays, reference 25). In addition, we obtained IL-la (2 .5 X 10' U/mg in thymocyte costimulation assays) and IL-1,B (5 X 10' U/mg in thymocyte costimulation assays) as gifts of Dr. Alan Shaw (Biogen, Geneva, Switzerland), and IFN-a (108 U/mg antiviral activity, consensus sequence), purchased from Amgen (Thousand Oaks, CA). It should be noted that our preparations of LT and IFN-y were expressed in mammalian cells and the preparation of IL-6 was expressed in a yeast system, resulting in glycosylated molecules . All of the cytokines used in these studies (except IL-6, for which specific antiserum is not available) could be neutralized by appropriate specific antisera and were unaffected in their endothelial-directed actions by 50 Ag/ml polymyxin B sulfate (Sigma Chemical Co.).
Surface expression of MHC antigens was quantitated by indirect immunofluorescence using a FACS Analyzer (Becton Dickinson & Co ., Mountain View, CA). Staining was performed as previously described (10) . mAbs used were W6/32 (26) for HLA-A,B antigens and LB3.1 (27) for HLA-DR antigens ; results with these antibodies were confirmed with BBM.1 (28) (reactive with 02 microglobulin) and L243 (29) (purchased from Becton Dickinson & Co., reactive with HLA-DR), respectively. Backgrounds for the staining were determined with nonbinding isotype-matched controls . Second antibody was a FITC-conjugated rabbit anti-mouse Ig serum (ICN Biochemicals, Cleveland, OH). Specific mRNA transcript levels for HLA-DR a chain were determined by Northern blotting on nylon membranes (GeneScreen; New England Nuclear, Boston, MA), using cytoplasmic RNA prepared by methods described elsewhere (12) . The specific probe used was a 0.6-kb Pst I fragment of an HLA-DR a cDNA clone (containing the a2 conserved domain); the complete cDNA (DB10) was a gift of Dr . Jack Strominger, Harvard University, Cambridge, MA . The probe was labeled by random oligonucleotide priming and blots were washed to a stringency of 0.5X standard sodium citrate, 1 .0% SDS at 65°C . The specificity of the hybridization was confirmed by the size of the relevant transcript (1 .3 kb for DR-a), based on comparisons to end-labeled Hind III a phage markers, electrophoresed, and blotted in parallel .
Results
The effects of cytokines upon EC expression of MHC antigens were examined by indirect immunofluorescence and FACS quantitation . As reported previously, EC express class I antigens but not class II antigens under standard culture conditions (9) . The surface density of class I antigens is quite homogenous, forming a tight log normal distribution, despite the fact that our EC cultures are derived from pooled donors . As a consequence of this homogeneity, it is reasonable to represent the population by the modal fluorescence (determined by the position of the peak channel for data expressed in the histogram mode of the FACS analyzer). In Fig. 1 , the difference between the modal fluorescence of W6/32 staining for class I antigens and that of isotype-matched irrelevant antibody is normalized to a relative fluorescence of 1 .0. As can be seen in the top panel (hatched bars), IFN-a and, to a lesser extent, TNF cause a concentrationdependent elevation of class I MHC antigens at 24 h, whereas IL-la does not; similarly, in the lower panel (hatched bars) IFN-# and, to a lesser extent, LT cause a concentration-dependent elevation of class I MHC antigens, whereas IL-I# does not. In both panels, an optimal concentration (200 U/ml) of IFN-y by itself (top line, black bars) causes an elevation of class I expression . The interesting result (remaining black bars) is that TNF and LT appear to synergize with IFNy, whereas IFN-a and IFN-,B show a combined effect with IFN-y that is less than additive . IL-1 species did not affect the actions of IFN-y in these experiments. The synergy of LT with IFN-y is further illustrated in Table I , where at all concentrations tested, the enhancement caused by combined mediators is essentially the product of the actions of either mediator alone. Interestingly, LT can also induce a further increase in class I MHC antigen expression beyond that produced by an optimal concentration of IFN-,B (1,000 U/ml, Table II ). This interaction is at least additive and may also be synergistic, as shown in Table III. An additional difference between LT and IFN-# is illustrated in Fig. 2 . In this experiment, the left hand FACS profiles show that neither LT nor IFN-,Q induce expression of class II MHC antigens by themselves . The right hand panels show that the maximally effective concentration of LT (100 U/ml) has little effect on the expression of HLA-DR induced by IFN-y, whereas IFN-,0, at its maximally effective concentration (1,000 U/ml), is profoundly inhibitory. The positive actions of LT and IFN-# in the presence of IFN-y on class I expression on the same samples (not shown) rule out the possibility that inhibition of class II expression by IFN-,Q is due to toxicity. Other experiments (not shown) indicate that TNF, like LT, has little effect on IFN-y-mediated class II induction, whereas IFN-a, like IFN-,3, is inhibitory. IL-Ia and IL-1,l have no effect on IFN-y induction of class II (not shown) . The distinction between LT and IFN-a on class 11 expression was confirmed by Northern blot analysis in the experiment shown in Fig. 3 ; 100 U/ml LT was only minimally inhibitory, whereas 1,000 U/ml IFN-,6 completely blocked the appearance of DRa mRNA caused by 200 U/ml IFNy in the control cultures. Previous studies (16) had suggested that TNF (and by implication LT) elevates class I transcripts by induction of an intermediary protein. Since the functional effects of LT and TNF have now been shown to be distinct from those of IFNaf, it seems highly unlikely that the actions of TNF or LT on MHC expression in EC could be mediated by stimulating the secretion of IFN-a or IFN-,l . It has been alternatively suggested that IL-6 (referred to by some investigators as IFN-02) might serve as the autocrine or paracrine second message for TNF modulation of MHC expression (18, 19) . To test this possibility, a recombinant preparation of IL-6 was compared with the actions of LT. As shown in Table IV , even at concentrations of 2 .5 ug/ml (equivalent to 8.7 x 10' U/ml of B cell stimulating factor 2 activity), our preparation of IL-6 does not mimic the actions of LT on EC ; i.e., it neither directly enhances class I MHC expression nor synergizes with IFN-y to produce a further increase of class I. LT or TNF cause further increases in class I antigen expression on cells already optimally stimulated by IFN-a or IFN-ft (i.e., with a concentration of cytokine greater than the maximally effective level) . Collectively, these observations suggest that there are at least three separate classes of MHC modulating cytokines: TNF/LT; IFN-a/a; and IFN-y . We propose that the net regulatory effect on EC expression of MHC antigens in vivo will depend upon the quantity and timing of cytokine generation in situ. The responses of EC to cytokines should be considered in the context of what is known regarding the responses of other cell types . In EC, we have seen little effect of LT or TNF on EC expression of class II antigens, and certainly no positive effect. However, certain tumor cell lines appear to express class II molecules directly in response to these cytokines (30, 31) . Furthermore, although IFN-y is a sufficient signal to induce class II expression in EC as in most other cell types (32) , recent studies have shown that TNF or LT serve as necessary cofactors with IFN-y for class II induction on pancreatic islet cells (33) . It remains to be seen if the EC pattern is the norm or one of several common variants.
The comparison of TNF or LT with the IFN family extends beyond the issue of MHC regulation. Like the IFNs, TNF and LT are growth inhibitory (34, 35) and produce an antiviral state (36, 37) . Since the actions of TNF (and presumably LT) on the MHC appear to involve synthesis of a protein (i.e., the mRNA increase is blocked by cycloheximide) . IFN-a or -Q were considered as potential second signals . Our inability to find IFN-,l mRNA induction in EC or dermal fibroblasts treated with TNF (16) was confirmed by others who found, instead, the induction of IL-6 (18), originally called IFN-N2 (38) or 26-kD protein (25) , or B cell stimulating factor 2 (39) . It has been proposed that IL-6 mediates the actions of TNF (and presumably LT) on MHC antigen expression (19) . Our initial experiments with a recombinant preparation of IL-6, biologically active as a B cell stimulating factor, are not consistent with this hypothesis in that IL-6 did not serve to regulate MHC expression in human EC . It remains to be determined whether other preparations or forms of IL-6 can modulate MHC expression, as there are reported discrepancies as to whether different preparations of this cytokine have antiviral activity (38, 40) .
Our comparisons of LT and TNF with IFN-a and IFN-,8 have both biological and clinical implications . For example, we would predict that TNF or LT will augment the immune enhancing actions of IFN-y . In the specific context of EC functions, TNF or LT would dramatically boost the IFN-y effect on expression of class I MHC antigens, rendering EC more potent at interacting with cytolytic T lymphocytes (8) . Furthermore, the coincident induction of membrane-associated IL-1 by TNF or LT (41) and of class II MHC antigens by IFN-y may show "biological synergy" in promoting the activation of helper T lymphocytes. Since the same T cells that produce IFN-y also appear to produce LT (42), the coincident exposure of EC to both cytokines appears quite likely . In contrast, we would predict that IFN-a and IFN-,8, which have also been found to inhibit IFNy-induced class II antigen expression on murine mononuclear phagocytes (43) (44) (45) , will be immunosuppressive . With specific regard to EC functions, the inhibition of class II MHC expression may, in turn, inhibit the recruitment of antigen-specific helper T lymphocytes and thus block the development of im-mune inflammation . The signals required for IFN-a and IFN-a secretion (e.g., dsRNA, virus infection, etc.) are quite distinct from those that elicit IFN-y and LT (e.g., antigen, T cell mitogens, etc.), and the inhibitory effects of IFN-a and IFN-# may not normally come into play in an immune response to antigen. However, the recent use of recombinant cytokines in various clinical settings (e.g., treatment of tumors or of viral infections) may have to be reevaluated in terms of whether an immunostimulatory agent (as in acquired immunodeficiency syndrome) or immunoinhibitory agent (as in a transplant recipient) would be preferable .
Summary
Recombinant preparations of TNF and lymphotoxin (LT) increase the expression of class I MHC antigens on cultured human endothelial cells (EC) without inducing expression of class II antigens. These actions are similar to those of rIFN-a or rIFN-,l. However, TNF and LT differ from IFN-a/# in that the former synergize with IFN-y for class I regulation whereas the latter do not. Furthermore, LT or TNF do not affect IFN-y-mediated class II induction at optimal class I inducing concentrations (100 U/ml), whereas IFN-a and IFN-0 (at their optimal concentrations of 1,000 U/ml) are strikingly inhibitory. LT and TNF also can further increase expression of class I antigens on cells already maximally stimulated by IFN-a or IFN-0. A recombinant preparation of IL-6 (formerly called 26-kD protein, IFN -N2, or B cell stimulating factor 2) was without effect on class I expression in EC. These data make it seem unlikely that the actions of LT or TNF on EC expression of MHC antigens are mediated through autocrine or paracrine production of IFN-a, IFN-,B or IL-6. More importantly, they suggest that LT or TNF are more likely to be immunostimulatory, whereas IFN-a or IFN-,B are more likely to be immunoinhibitory in vivo, a consideration of potential relevance for cytokine administration to various patient populations.
